OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. OSI specializes in the discovery and development of molecular targeted therapies, and is listed in the NASDAQ Biotechnology Index. Though oncology is the top priority for OSI, research and development targeting type 2 diabetes and obesity is conducted through their U.K. subsidiary Prosidion Limited.

PropertyValue
dbpedia-owl:Company/netIncome
  • -582200000
dbpedia-owl:Company/product
dbpedia-owl:Organisation/foundationDate
  • 1983-01-01 00:00:00 (xsd:date)
dbpedia-owl:Organisation/keyPersonPosition
  • Colin Goddard, CEO
    Michael G. Atieh, CFO
    Robert A. Ingram, Chairman
dbpedia-owl:Organisation/location
dbpedia-owl:Organisation/numberOfEmployees
  • 554 (xsd:integer)
dbpedia-owl:Organisation/revenue
  • 375700000
dbpedia-owl:foundationDate
  • 1983-01-01 00:00:00 (xsd:date)
dbpedia-owl:keyPersonPosition
  • Colin Goddard, CEO
    Michael G. Atieh, CFO
    Robert A. Ingram, Chairman
dbpedia-owl:location
dbpedia-owl:netIncome
  • -582200000
dbpedia-owl:numberOfEmployees
  • 554 (xsd:integer)
dbpedia-owl:product
dbpedia-owl:revenue
  • 375700000
dbpprop:abstract
  • OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. OSI specializes in the discovery and development of molecular targeted therapies, and is listed in the NASDAQ Biotechnology Index. Though oncology is the top priority for OSI, research and development targeting type 2 diabetes and obesity is conducted through their U.K. subsidiary Prosidion Limited. OSI has also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen for Age-related macular degeneration; however, acquisition of the firm Eyetech, meant to provide control over this product and diversify the company, has been unsuccessful, ending in . As of mid-2007, OSI's revenues are based primarily on proceeds from Tarceva sales and royalty payments related to dipeptidyl-peptidase IV inhibitor intellectual property.
dbpprop:companyLogo
dbpprop:companyName
  • OSI Pharmaceuticals, Inc.
dbpprop:companyType
  • Public ()
dbpprop:foundation
  • 1983 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:homepage
dbpprop:industry
  • Biopharmaceuticals & Biotherapeutics
dbpprop:keyPeople
  • Colin Goddard, CEO Michael G. Atieh, CFO Robert A. Ingram, Chairman
dbpprop:location
dbpprop:netIncome
  • $-582.2 Million USD (2006)
dbpprop:numEmployees
  • 554 (2007-02)
dbpprop:products
dbpprop:reference
dbpprop:revenue
  • 375700000
dbpprop:slogan
  • Shaping Medicine, Changing Lives
dbpprop:wikiPageUsesTemplate
dbpprop:wordnet_type
rdf:type
rdfs:comment
  • OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. OSI specializes in the discovery and development of molecular targeted therapies, and is listed in the NASDAQ Biotechnology Index. Though oncology is the top priority for OSI, research and development targeting type 2 diabetes and obesity is conducted through their U.K. subsidiary Prosidion Limited.
rdfs:label
  • OSI Pharmaceuticals
owl:sameAs
skos:subject
foaf:homepage
foaf:name
  • OSI Pharmaceuticals, Inc.
foaf:page
is dbpprop:disambiguates of
is owl:sameAs of